

 
 
Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist
 
Most Trending
SXTP
60 Degrees Pharmaceutical
$1.38
 Login to see 60 Degrees Pharmaceutical (SXTP)  Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid
  Login to see 60 Degrees Pharmaceutical (SXTP)  Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid Risk Analysis

Earnings are forecast to decrease
Chart
$1.44 (-4.17%)
$1.35 (+2.22%)
$2.95 (-53.22%)
$0.97 (+42.27%)
SXTP has Low Risk Level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk
Risks Indicators

Price under $5

Low volume

 
SXTP overall standing based on key factors, offering insights into analysts perspectives and market expectations.
 Hover over the category for more information
Hover over the category for more information
Earnings
Earnings
Rating
Rating
Momentum
Momentum
Activity
Activity
Future
Future

Earnings are forecast to decrease

SXTP Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
 
 
SXTP Street view is bullish but have mixed views on the near-term outlook
Average key support and resistance price levels.
 Login to display
  Login to displaySXTP Earnings
The TTM reflects 12-month period, providing review of SXTP financial performance.
The company financial health has shown minor improvement, but significant issues remain
Financial Score
What is SXTP current stock price?
What are SXTP stock strengths?
What risks are associated with SXTP stock?
When is SXTP next earnings report?
What is SXTP market cap and volume?
What is SXTP's current Stock IQ?
Should I buy SXTP stock right now?
Is SXTP a Strong Buy right now?
What does a 'Strong Buy' rating mean for SXTP?
What does a 'Strong Sell' rating mean for SXTP?
What factors influence SXTP's Stock IQ?
 
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
SXTP
60 Degrees Pharmaceutical
Current Price
$1.38
Stock Insights
Risk Analysis

Earnings are forecast to decrease
 Login to unlock 60 Degrees Pharmaceutical (SXTP) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid
  Login to unlock 60 Degrees Pharmaceutical (SXTP) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid  
Chart
$1.44 (-4.17%)
$1.35 (+2.22%)
$2.95 (-53.22%)
$0.97 (+42.27%)
SXTP Analysts Opinion
 
SXTP Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
 Hover over the category for more information
Hover over the category for more information
Earnings
Earnings
Rating
Rating
Momentum
Momentum
Activity
Activity
Future
Future

Earnings are forecast to decrease

SXTP Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
 
 
SXTP Street view is bullish but have mixed views on the near-term outlook
SXTP has Low Risk Level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk
Risks Indicators

Price under $5

Low volume

Average key support and resistance price levels.
 Login to display
  Login to displaySXTP Earnings
The TTM data reflects the most recent 12-month period, providing overview of SXTP financial performance.
SXTP Financial Health
The company financial health has shown minor improvement, but significant issues remain
Financial Score
SXTP Latest Analysis
60 Degrees Pharmaceuticals Reports Positive Data From First Patient In Relapsing Babesiosis Study . (RTTNews) - 60 Degrees Pharmaceuticals Inc. (SXTP) Wednesday announced encouraging findings from its trial of relapsing babesiosis in immunosuppressed patients reporting that the first patient who has completed the ARAKODA regimen tested negative for babesiosis.
Wed Oct 15, 2025
 
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
SXTP Stock trends
SXTP Stock performance
SXTP Stock analysis
SXTP investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS"). 
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.